Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Navidea Biopharmaceuticals Inc (NAVB)

Navidea Biopharmaceuticals Inc (NAVB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,678
  • Shares Outstanding, K 32,151
  • Annual Sales, $ 530 K
  • Annual Income, $ -11,730 K
  • 60-Month Beta 1.36
  • Price/Sales 14.20
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NAVB with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.57
  • Most Recent Earnings -0.25 on 11/14/22
  • Next Earnings Date 11/15/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -401.43%)
  • Historical Volatility 80.57%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 837.58% on 11/08/22
  • IV Low 0.00% on 11/29/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 1,054
  • Open Int (30-Day) 1,012

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2000 +19.40%
on 11/25/22
0.2929 -18.47%
on 11/16/22
+0.0062 (+2.67%)
since 10/28/22
3-Month
0.2000 +19.40%
on 11/25/22
0.3850 -37.97%
on 08/30/22
-0.1362 (-36.32%)
since 08/29/22
52-Week
0.2000 +19.40%
on 11/25/22
1.3400 -82.18%
on 12/14/21
-1.0612 (-81.63%)
since 11/26/21

Most Recent Stories

More News
Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.2388 (+1.62%)
Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.2388 (+1.62%)
Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.2388 (+1.62%)
Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.2388 (+1.62%)
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.2388 (+1.62%)
Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.2388 (+1.62%)
Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.2388 (+1.62%)
Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.2388 (+1.62%)
Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney’s Fees

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.2388 (+1.62%)
Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the...

NAVB : 0.2388 (+1.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents for diseases such as cancer and Alzheimer. The Company's radiopharmaceutical development programs include: Lymphoseek(R), AZD4694 and...

See More

Key Turning Points

3rd Resistance Point 0.2784
2nd Resistance Point 0.2689
1st Resistance Point 0.2539
Last Price 0.2388
1st Support Level 0.2294
2nd Support Level 0.2199
3rd Support Level 0.2049

See More

52-Week High 1.3400
Fibonacci 61.8% 0.9045
Fibonacci 50% 0.7700
Fibonacci 38.2% 0.6355
Last Price 0.2388
52-Week Low 0.2000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar